Agenus’ Post

Are you interested in “real” Real World Evidence, which is gathered from patients directly using our OWise platform? Check out this post showcasing the latest work of our collaborators!

What sparks your interest when you think of oncology innovation and the future of cancer care? Learn from leading oncology experts as we explore some of the key developments in the space and what they may mean for cancer care in our new video series ‘Cancer Dialogue’. Stay tuned over #ESMO24 as we share the first edition of the series. What would you like to see discussed in the ‘Cancer Dialogue’ series? Comment below and have your say!

Congrats Sandra Dunn & PMD Team on the Late Breaker at #SABCS. RKS2 is a compelling emerging target downstream of the Pi3K & MEK/ERK pathways regulating both NFkB inflammation & G2/M cell cycle control. With >70% of TNBC patients RSK2 High, this is an 'off the radar' target for which a safe & active clinical asset in PMD-026 is ready to be furthered deployed, having already shown preliminary promise. Having lost someone dear to TNBC, let's give this novel biology a shot at showing benefit in mono- & combination.

How can technology shape the future of #PatientNavigation to deliver optimal care? Hear from our 2023 meeting series participant, Ricki Fairley, CEO of TOUCH The Black Breast Cancer Alliance and a 12-year Triple Negative Breast Cancer Survivor. #Tech4CancerNavigation

🧐Check out the #Article "Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis" 👥by Sandra M. Swain, MD, FACP, FASCO et al. Georgetown University Medical Center Find the full paper here⏭️ https://lnkd.in/dgqEuksT Keywords: dual HER2 targeting; early breast cancer; event-free survival; HER2; pathologic complete response; pertuzumab; trastuzumab

ICYMI: In this episode of OncLive On Air, Ryan Merkow, MD, MS, of the University of Chicago Medicine Comprehensive Cancer Center, and Louise Catherine Connell, MB BCh BAO, BMedSc, of Memorial Sloan Kettering Cancer Center, discuss the use of HAI therapy for patients with colorectal cancer. https://lnkd.in/eZsDpEin

🔬Attended an insightful keynote webinar 'Spotlight on Antibody-Drug Conjugates in Cancer', hosted by Springer Medicine yesterday. Grateful for the opportunity to learn from experts about the latest developments in the ADC space with respect to breast and lung cancer. The session shed light on some of the ongoing clinical trials with 3rd generation ADCs, sharing results from different trial phases and addressing questions on the toxicity profile of these ADCs. The webinar ended with a wonderful Q&A session where the experts answered questions from viewers, highlighting the importance of understanding mechanisms of resistance and improving ADC design for improving prognosis in patients. Looking forward to attending other such insightful webinars in the future! #cancerresearch #adcs #springermedicine #webinarinsights #antibodydrugconjugates #precisionmedicine #precisiononcology

Unveiling the most powerful currency in the world - The Cancer Currency! Crafted by VML HEALTH and EUROPA DONNA - The European Breast Cancer Coalition, it symbolizes the inherent value of those living with metastatic breast cancer. Join the movement that secures recognition and funding within Europe’s Beating Cancer Plan. More in Ad Age here: https://bit.ly/3SSBQZO

Prevention! prevention! Cancer screening is the key message at the World Cancer Day!

How do you make the decision to end or extend your HR+, early-stage breast cancer patients’ endocrine therapy after their first initial 5 years? Let Breast Cancer Index help take the guess work out of your decision. Nice talk by Drs. Rena Callahan and VK Gadi.